There are always people in society who believe that new and expensive drugs are more effective. Especially for patients with chronic and stubborn diseases, they always try their best to find new and expensive drugs, hoping to achieve immediate results. It is understandable that patients feel this way, but this kind of thinking is obviously blind.
We all know that although a new drug may have good clinical efficacy after clinical use, a large part of these drugs have not been tested for a long time in terms of actual effectiveness and adverse reactions. The number of cases is also limited, making it difficult to fully and accurately reflect their actual performance. As time goes on, a large part of these new drugs are eliminated due to poor efficacy or severe adverse reactions. There are only a few new drugs that can withstand the test and actually surpass the efficacy of existing drugs.
For example, in the 1970s, a new anti-tuberculosis drug called Rifampicin was introduced. At that time, its promotion almost reached an idealized level, claiming to have anti-viral, anti-leprosy, and anti-cancer effects. After several years of clinical practice and basic research, it was found that its anti-tuberculosis effect was only comparable to Isoniazid, but its price was dozens of times higher. When used alone, Mycobacterium tuberculosis easily developed resistance to Rifampicin, rendering it ineffective. Some patients may also experience side effects such as aplastic anemia and liver damage after using it.
The fact proves that the emergence of a new drug is only a process of exploration, practice, and verification. Patients should not blindly pursue it. When using medication, remember to treat the symptoms and focus on significant efficacy. Avoid blindly believing in new or expensive drugs.
